Want to see HK:2407 full AI Analyst Report?
Gaush Meditech Ltd. (2407) Stock Price & Analysis
2407 Stock Chart & Stats
- Day’s Range
- HKD 4.34 - HKD 4.40
- 52-Week Range
- HKD 3.80 - HKD 9.49
- Previous Close
- HKD 4.40
- Volume
- N/A
- Average Volume (3M)
- 16.02K
- Market Cap
- HKD 650.71M
- Enterprise Value
- HKD 776.20M
- Total Cash (Recent Filing)
- HKD 358.11M
- Total Debt (Recent Filing)
- HKD 402.50M
- Price to Earnings (P/E)
- 7.2
- Beta
- 0.68
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 23, 2025
- Dividend Yield
- 6.82%
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet
The lower debt-to-equity ratio and stronger equity base indicate materially improved financial stability compared with earlier periods. Reduced leverage should give Gaush Meditech more flexibility to fund operations, absorb business volatility, and pursue growth without excessive balance-sheet strain.
Positive Cash Generation
Positive operating and free cash flow provide internally generated funding for business needs and reduce reliance on external financing. The 2025 improvement also indicates that the company can convert a meaningful share of earnings into cash, supporting financial resilience over the coming quarters.
Profitable Medtech Operations
Gaush Meditech remains profitable with a substantial gross margin, showing that its medical-device products retain economic value after direct costs. Continued positive earnings can support reinvestment and cash generation, even though profitability is below the stronger level reported in 2023.
Bears Say
Revenue Contraction
The recent revenue decline points to a weaker near-term growth trajectory and may indicate softer demand or pricing pressure across the company’s markets. If this persists, slower scale expansion could limit operating leverage, reduce reinvestment capacity, and make earnings improvement more difficult.
Margin Compression
The substantial fall in net margin shows that positive revenue does not consistently translate into comparable earnings power. Ongoing margin pressure would weaken cash generation and returns, while the history of losses highlights the risk that profitability may remain volatile rather than structurally dependable.
Uneven Cash Conversion
Variable conversion of profits into free cash flow makes funding capacity less predictable and complicates long-term capital allocation. Although 2025 cash generation improved, the weaker prior year shows that reported earnings may not reliably produce equivalent liquidity through the business cycle.
Gaush Meditech Ltd. News
Gaush Meditech Grants Heidelberg Exclusive Global Rights to T3 Corneal Imaging System
The latest announcement is out from Gaush Meditech Ltd. ( ($HK:2407) ). Gaush Meditech’s subsidiary Gaush Neotech has signed a five-year exclusive agency agreement with Germany’s Heidelberg Engineering to distribute
2407 FAQ
What was Gaush Meditech Ltd.’s price range in the past 12 months?
What is Gaush Meditech Ltd.’s market cap?
When is Gaush Meditech Ltd.’s upcoming earnings report date?
How were Gaush Meditech Ltd.’s earnings last quarter?
Is Gaush Meditech Ltd. overvalued?
Does Gaush Meditech Ltd. pay dividends?
What is Gaush Meditech Ltd.’s EPS estimate?
How many shares outstanding does Gaush Meditech Ltd. have?
What happened to Gaush Meditech Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Gaush Meditech Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Gaush Meditech Ltd. Stock Smart Score
Company Description
Gaush Meditech Ltd.
Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally. The company's operations are divided into four main divisions: Proprietary Products, Distribution, Technical Services, and Other Business Ventures. Its advanced ophthalmic instruments are crucial for the diagnosis, treatment, and surgical intervention of a broad spectrum of eye conditions, including vitreoretinal disorders, cataracts, glaucoma, refractive errors, ocular surface diseases, and issues in optometry and pediatric ophthalmology. The Proprietary Products division focuses on creating and producing its own line of surgical apparatus, accompanying software, intraocular lenses, and equipment for diagnosing and treating eye ailments, along with their associated consumables. Conversely, the Distribution division is responsible for selling diagnostic devices, equipment for ocular fundus examination, surgical and treatment instruments, and related consumables. The Technical Services segment provides essential support, covering warranty services, maintenance, and the supply of post-sales consumables. Lastly, the Other Business Ventures division handles equipment rental, agent registration services, and the licensing of intellectual property. Gaush Meditech Ltd. reaches its clientele—comprising public and private hospitals, among other customers—through both direct sales and a network of distributors. The company was established in 1998 and has its corporate headquarters situated in Beijing, China.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Xinwei Liu
- Employees
- 893
- Website
- www.gaush.com
- Address
- CN
Gaush Meditech Ltd. (2407) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 5 | 7 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 7 | 0 | 5 |
